Obbligazioni societarie Pharmaceutical

lorenzo63

Age quod Agis
Credo che, accanto al Monitor Chimica, debba essere istituito un (almeno) newsflow sulle Società Pharma, i cui nomii, ricordo, sono molte volte comuni, a quelle della Chimica: penso ad esempio a Solvay o a Basf o a tantissime altre...Come solito gli interventi sono ben accetti (anche le richieste, ovvio:))
 
Sovay

Ne abbiamo già parlato nel Monitor chimica:

La Solvay sta cercando di vendere la divisione farmaceutica la quale è valutata tra 5 e 6 miliardi di euro...
La Solvay non ha voluto rilasciare commenti sul perchè vuole vendere la divisione pharma, inoltre abbandonerebbe quella a + elevata crescita e piu' redditizia.

Acquirenti probabili potrebbero essere Sanofi Aventis, Bauer, Astra Zeneca Abbott laboratioires.

Il settore ha avuto ricavi pari al 28% del fatturato Solvay. Produce farmaci antiipertensivi, anticolesterolo, per la cura del Parkinsons.
 
Novartis Moves Closer To Producing Swine Flu Vaccine "La Maiala ;-)"

Riguarda anche Solvay, monitorata nel "Report Chimica"..

ZURICH (Dow Jones)--Pharmaceutical company Novartis AG (NOVN.VX) Friday released positive data on a vaccine for swine flu, a day after the World Health Organization declared the first influenza pandemic in more than 40 years.

Novartis said it had produced its first batch of the vaccine for influenza AH1N1, the strain which triggered the WHO alert.

It said the vaccine was manufactured weeks ahead of expectations using cell-based technology, allowing for production without the need to adapt the virus strain to grow in eggs. It plans to start clinical trials with that vaccine in July and expects to get a license in the fall of 2009.

Analysts said it is important the batch has been produced by cell-based manufacture. This will enables Novartis to "beef up speed so you can have a vaccine in large quantities in the fall," Vontobel analyst Andrew Weiss said. He has a buy rating and a target price of CHF58.

More than 30 governments have asked Novartis to supply the vaccine ingredients, the company said.

The WHO's pandemic declaration will require all countries, including the dozens that haven't yet reported any cases, to launch pandemic-prevention plans.

Rivals such as GlaxoSmithKline Plc (GSK), Sanofi-Aventis (SNY) and Solvay SA (SOLB.BT) have recently said they have received orders for, or that they are ready to start production of vaccines to help protect against the new swine flu virus.

Some companies already sell anti-viral drugs that are effective against new influenza A (H1N1) virus: Switzerland's Roche Holding AG (ROG.VX) markets Tamiflu, and U.K.-based GlaxoSmithKline has Relenza.

On the Swiss bourse at 0740 GMT, shares in Novartis were up 2.2%, or CHF0.94 higher at CHF44.04 in a slightly firmer general market. The stock is down 17% from year-ago levels, however
 
Credo che, accanto al Monitor Chimica, debba essere istituito un (almeno) newsflow sulle Società Pharma, i cui nomii, ricordo, sono molte volte comuni, a quelle della Chimica: penso ad esempio a Solvay o a Basf o a tantissime altre...Come solito gli interventi sono ben accetti (anche le richieste, ovvio:))

un monitor 'pharma' non può non includere Pfizer, GSK, Novartis, Schering-Plough (si è fusa con Merck ??), Roche, J&J, Astra Zeneca, Ely Lylly per poi passare alle minori come Genentech e Actelion o ai venditori di generici come Actavis e Ratiopharm, e un occhio alle piccole (Recordati) e piccolissime italiane come Cosmo e Pierrel :eek:
 
Drugmakers Offer $80 Billion Boost to Obama’s Overhaul Effort

By Nicole Gaouette and Nicholas Johnston
June 21 (Bloomberg) -- Drugmakers agreed to spend as much as $80 billion over 10 years to make it easier for elderly Americans to afford medicine, a move President Barack Obama hailed as “a turning point” in his effort to overhaul the nation’s health-care system.
The arrangement, negotiated over months with U.S. Senator Max Baucus, chairman of the Finance Committee, with the participation of the Obama administration, shrinks the so- called doughnut hole in Medicare’s prescription-drug program. The companies will discount as much as 50 percent of the cost of brand-name medicines, according to PhRMA, the Washington- based industry trade group that represents such drugmakers as Pfizer Inc. and Eli Lilly & Co.
“We are at a turning point in America’s journey toward health-care reform,” Obama said in a statement. “Key sectors of the health-care industry acknowledge what American families and businesses already know -- that the status quo is no longer sustainable.”
Still, the question of how to pay for the country’s biggest expansion in health-care coverage in more than four decades looms large in Congress. The announcement of an accord late yesterday capped a week in which Republicans challenged the price tag of Obama’s plans. The U.S. Chamber of Commerce, the largest business group, began a campaign against proposals being considering in Congress, including a requirement that employers provide health insurance to their workers.
Campaign Pledge
Congress is working against an October deadline that Obama, a Democrat, set for signing the legislation into law. As a presidential candidate he pledged to expand coverage to the 46 million people who lack health insurance while lowering the cost of a system of care that makes up 17 percent of the economy.
Last week, the Congressional Budget Office estimated that a version of an overhaul being considered by Baucus’s panel would cost at least $1.6 trillion. Baucus, a Montana Democrat, put off releasing a draft of his legislation while his panel looked for more savings.
“This has been a bad week, and we wanted to show the administration and the American people that we were doing everything we can to help get comprehensive health reform,” said Ken Johnson, senior vice president at PhRMA, in a telephone interview. The $80 billion represents “the limit of what we’re willing to pay for” over 10 years to extend discounts to the elderly.
PhRMA, short for the Pharmaceutical Research and Manufacturers of America, was one of six groups in the health- care industry that pledged May 11 at the White House to help reduce U.S. medical spending by $2 trillion over a decade.
The Hole
Under Medicare’s prescription drug benefit program, known as Part D, patients buy medicines through conventional or mail- order pharmacies. They pay the first $295 of costs, then the plan covers 75 percent of purchases until the total reaches $2,700, according to Medicare’s explanation of the program. Patients must then pay all their costs until spending $4,350 out pocket under the “doughnut hole.” Thereafter, they make a small co-payment for each drug until the end of the year. Insurance companies sell plans providing the drug benefit.
Many people stop taking their medicines when they enter the coverage gap, Johnson said. Drug companies, among them Merck & Co., often have assistance programs.
“With this new proposal we will go the extra step and offer direct savings to Medicare Part D beneficiaries in the coverage gap regardless of their income,” said Richard T. Clark, the chairman and chief executive officer of Merck, in a statement. The Whitehouse Station, New Jersey, company makes the diabetes and osteoporosis drugs Januvia and Fosamax.
Soaring Costs
Obama argues that his plan is aimed at curtailing health- care costs, which PricewaterhouseCoopers said in a report last week will rise 9 percent next year. Health care’s share of the nation’s economy may double to 34 percent by 2040 if nothing is done to change the current system, the White House Council of Economic Advisers said June 2.
AARP, the Washington-based advocacy group for Americans 50 and older, praised yesterday’s accord.
“We look forward to studying the details of this agreement, and we will work with the administration, Congress and other stakeholders to enact comprehensive health care reform this year,” said Nancy LeaMond, AARP executive vice president, in a statement.

http://www.bloomberg.com/apps/news?pid=20601087&sid=a2LmS5Qfv344
 
Elenco pharma (chiedo scusa per il tempo trascorso) ...

12639347001.jpg



Altro?

:)
 
un monitor 'pharma' non può non includere Pfizer, GSK, Novartis, Schering-Plough (si è fusa con Merck ??), Roche, J&J, Astra Zeneca, Ely Lylly per poi passare alle minori come Genentech e Actelion o ai venditori di generici come Actavis e Ratiopharm, e un occhio alle piccole (Recordati) e piccolissime italiane come Cosmo e Pierrel :eek:

Magari Lorenzo voleva arrostirsi una bistecchina di maiale, tu invece hai messo sul barbecue un quarto di bue... :-o :D
 
Novartis: Ratings ed emissioni

Credit ratings of Novartis AG

Moody’sStandard & Poor’sFitchShort termP-1A-1+F1+Long termAa2AA-AAOutlookStableStableStable



Novartis Finance S.A.

Principal amountEUR 1,500,000,000ISINXS0432810116IssuerNovartis Finance S.A., LuxembourgGuarantorNovartis AG, SwitzerlandTypeSenior unsecuredCoupon4.250%Coupon payment dateJune 15DocumentationEMTN ProgrammeFirst settlement dateJune 15, 2009Issue price99.757Maturity dateJune 15, 2016Joint book-runnersBarclays Bank, BNP Paribas, Deutsche BankBloombergNOVART41/4ListingLondon Stock Exchange

Novartis Capital Corp.

Principal amountUSD 2,000,000,000ISINUS66989HAA68IssuerNovartis Capital Corp., United StatesGuarantorNovartis AG, SwitzerlandTypeSenior unsecuredCoupon4.125%Coupon payment datesFebruary 10, August 10DocumentationSEC registered shelf registrationFirst settlement dateFebruary 10, 2009Issue price99.897Maturity dateFebruary 10, 2014Joint book-runnersJP Morgan, Bank of America, Citi, Goldman SachsBloombergNOVART41/8

Novartis Securities Investment Ltd.

Principal amountUSD 3,000,000,000ISINUS66989GAA85IssuerNovartis Securities Investment Ltd., BermudaGuarantorNovartis AG, SwitzerlandTypeSenior unsecuredCoupon5.125%Coupon payment datesFebruary 10, August 10DocumentationSEC registered shelf registrationFirst settlement dateFebruary 10, 2009Issue price99.822Maturity dateFebruary 10, 2019Joint book-runnersJP Morgan, Bank of America, Citi, Goldman SachsBloombergNOVART51/8

Novartis Securities Investment Ltd.

Principal amountCHF 700,000,000ISINCH0043088183IssuerNovartis Securities Investment Ltd., BermudaGuarantorNovartis AG, SwitzerlandTypeSenior unsecuredCoupon3.500%Coupon payment dateJune 26DocumentationSwiss stand-alone documentationFirst settlement dateJune 26, 2008Issue price100.32Maturity dateJune 26, 2012Joint book-runnersCredit Suisse, UBSBloombergNOVART3½ListingSIX Swiss Exchange

Novartis AG

Principal amountCHF 800,000,000ISINCH0043089009IssuerNovartis AG, SwitzerlandTypeSenior unsecuredCoupon3.625%Coupon payment dateJune 26DocumentationSwiss stand-alone documentationFirst settlement dateJune 26, 2008Issue price100.3500Maturity dateJune 26, 2015Joint book-runnersCredit Suisse, UBSBloombergNOVART35/8ListingSIX Swiss Exchange
 
Bayer: Emissioni

Bonds issued


Issuer:
Currency:
Current volume:
Format:
Year of issue:
Maturity:
Coupon:
ISIN No:

Bayer AG
EUR
300,000,000
EMTN
2007
04-10-2010
Variable
XS0295204969
Issuer:
Currency:
Current volume:
Format:
Year of issue:
Maturity:
Coupon:
ISIN No:

Bayer Holding Ltd.
JPY
10,000,000,000
EMTN
2007
06-28-2010
1.585
XS0307873314
Issuer:
Currency:
Current volume:
Format:
Year of issue:
Maturity:
Coupon:
ISIN No:

Bayer AG
EUR
200,000,000
EMTN
2008
01-27-2011
4.000
XS0406910496
Issuer:
Currency:
Current volume:
Format:
Year of issue:
Maturity:
Coupon:
ISIN No:

Bayer AG
EUR
200,000,000
EMTN
2007
04-11-2011
4.375
XS0295205347
Issuer:
Currency:
Current volume:
Format:
Year of issue:
Maturity:
Coupon:
ISIN No:
Bayer AG
EUR
2,000,000,000
EMTN
2002
04-10-2012
6.000
XS0145758040
Issuer:
Currency:
Current volume:
Format:
Year of issue:
Maturity:
Coupon:
ISIN No:

Bayer Holding Ltd.
JPY
30,000,000,000
EMTN
2007
06-28 -2012
Variable
XS0307884436
Issuer:
Currency:
Current volume:
Format:
Year of issue:
Maturity:
Coupon:
ISIN No:

Bayer Holding Ltd.
JPY
15,000,000,000
EMTN
2007
06-28-2012
1.955
XS0307884352
Obligor:
Currency:
Issue volume:
Format:
Year of issue:
Maturity:
Coupon:
ISIN No:
Bayer Corporation
USD
409,385,000
144A
2002
01-02-2013
6.100
US07274AAA97
Issuer:

Currency:

Current volume:

Format:

Year of issue:

Maturity:

Coupon:

ISIN No:
Bayer AG
EUR
1,000,000,000
EMTN
2006
05-23-2013
4.500
XS0255605825
Issuer:
Currency:
Current volume:
Format:
Year of issue:
Maturity:
Coupon:
ISIN No:
Bayer Holding Ltd.
JPY
10.000.000.000
EMTN
2008
07-04-2013
Variable
XS0374144847
Issuer:
Currency:
Current volume:
Format:
Year of issue:
Maturity:
Coupon:
ISIN No:

Bayer Capital Corporation
EUR
1,300,000,000
EMTN
2009
09-26-2014
4.625
XS0420117383
Issuer:
Currency:
Current volume:
Format:
Year of issue:
Maturity:
Coupon:
ISIN No:
Bayer Holding Ltd.
JPY
15,000,000,000
EMTN
2008
12-19-2018
3.575
XS0405675009

Issuer:

Currency:

Current volume:

Format:

Year of issue:

Maturity:

Coupon:

ISIN No:

Prospectus:

Development of Gross Cash Flow Ratio:


Bayer AG
EUR
1,300,000,000
Stand-Alone (Hybrid)
2005
07-29-2105
5,000
XS0225369403

PDF / 496 KB collectBayer_Bond_2005_Hybrid_Prospectus.pdf Bayer_Bond_2005_Hybrid_Prospectus.pdf

PDF / 60 KB collectHybrid_Bond_Bruttocashflow_Ratio_e.pdf Hybrid Bond Gross Cash Flow Ratio

Issuer:

Currency:

Current volume:

Format:

Year of issue:

Maturity:

Coupon:

ISIN No:
Bayer Corporation
USD
200,000,000
144A
1995
10-01-2015
7.125
US072732AA85
Issuer:

Currency:

Current volume:

Format:

Year of issue:

Maturity:

Coupon:

ISIN No:
Bayer AG
GBP
350,000,000
EMTN
2006
05-23-2018
5.625
XS0255605239
Issuer:

Currency:

Current volume:

Format:

Year of issue:

Maturity:

Coupon:

ISIN No:
Bayer Corporation
USD
350,000,000
144A
1998
02-15-2028
6.650
US072732AC42
 

Users who are viewing this thread

Back
Alto